KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Asset Writedowns and Impairment: 2016-2024

Historic Asset Writedowns and Impairment for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $96.6 million.

  • Amneal Pharmaceuticals' Asset Writedowns and Impairment rose 3.08% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.5 million, marking a year-over-year increase of 24.34%. This contributed to the annual value of $96.6 million for FY2024, which is 29.29% up from last year.
  • Amneal Pharmaceuticals' Asset Writedowns and Impairment amounted to $96.6 million in FY2024, which was up 29.29% from $74.7 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Asset Writedowns and Impairment peaked at $96.6 million during FY2024, and registered a low of $51.1 million during FY2022.
  • Its 3-year average for Asset Writedowns and Impairment is $74.1 million, with a median of $74.7 million in 2023.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Asset Writedowns and Impairment tumbled by 56.46% in 2020 and then surged by 46.17% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Asset Writedowns and Impairment stood at $75.2 million in 2020, then dropped by 27.35% to $54.7 million in 2021, then fell by 6.52% to $51.1 million in 2022, then soared by 46.17% to $74.7 million in 2023, then climbed by 29.29% to $96.6 million in 2024.